- Home
- TD vs VRTX Comparison
TD vs VRTX Comparison
Compare TD & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TD
- VRTX
- Stock Information
- Founded
- TD 1855
- VRTX 1989
- Country
- TD Canada
- VRTX United States
- Employees
- TD N/A
- VRTX N/A
- Industry
- TD
- VRTX EDP Services
- Sector
- TD
- VRTX Technology
- Exchange
- TD Nasdaq
- VRTX Nasdaq
- Market Cap
- TD 94.8B
- VRTX 104.8B
- IPO Year
- TD N/A
- VRTX 1991
- Fundamental
- Price
- TD $57.26
- VRTX $427.89
- Analyst Decision
- TD Buy
- VRTX Buy
- Analyst Count
- TD 2
- VRTX 30
- Target Price
- TD $83.50
- VRTX $503.92
- AVG Volume (30 Days)
- TD 2.7M
- VRTX 2.0M
- Earning Date
- TD 02-27-2025
- VRTX 02-03-2025
- Dividend Yield
- TD 5.22%
- VRTX N/A
- EPS Growth
- TD N/A
- VRTX N/A
- EPS
- TD 3.39
- VRTX N/A
- Revenue
- TD $38,208,826,702.00
- VRTX $10,625,800,000.00
- Revenue This Year
- TD N/A
- VRTX $12.56
- Revenue Next Year
- TD $4.69
- VRTX $8.34
- P/E Ratio
- TD $16.91
- VRTX N/A
- Revenue Growth
- TD 7.78
- VRTX 10.06
- 52 Week Low
- TD $51.25
- VRTX $377.85
- 52 Week High
- TD $64.91
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- TD 71.33
- VRTX 51.93
- Support Level
- TD $53.03
- VRTX $397.25
- Resistance Level
- TD $57.89
- VRTX $425.49
- Average True Range (ATR)
- TD 0.82
- VRTX 8.23
- MACD
- TD 0.50
- VRTX 4.23
- Stochastic Oscillator
- TD 88.02
- VRTX 92.07
About TD Toronto Dominion Bank (The)
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, US retail banking, and wholesale banking. The bank's US operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.